HomeCompareMBXBF vs EQR

MBXBF vs EQR: Dividend Comparison 2026

MBXBF yields 1162.79% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MBXBF wins by $71037548.31M in total portfolio value
10 years
MBXBF
MBXBF
● Live price
1162.79%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71037548.35M
Annual income
$60,758,695,090,499.19
Full MBXBF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MBXBF vs EQR

📍 MBXBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMBXBFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MBXBF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MBXBF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MBXBF
Annual income on $10K today (after 15% tax)
$98,837.21/yr
After 10yr DRIP, annual income (after tax)
$51,644,890,826,924.31/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, MBXBF beats the other by $51,644,890,823,677.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MBXBF + EQR for your $10,000?

MBXBF: 50%EQR: 50%
100% EQR50/50100% MBXBF
Portfolio after 10yr
$35518774.19M
Annual income
$30,379,347,547,159.40/yr
Blended yield
85.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MBXBF
No analyst data
Altman Z
1.4
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MBXBF buys
0
EQR buys
0
No recent congressional trades found for MBXBF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMBXBFEQR
Forward yield1162.79%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$71037548.35M$40.5K
Annual income after 10y$60,758,695,090,499.19$3,819.61
Total dividends collected$70267668.95M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: MBXBF vs EQR ($10,000, DRIP)

YearMBXBF PortfolioMBXBF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$126,979$116,279.07$11,248$547.57+$115.7KMBXBF
2$1,515,775$1,379,907.30$12,701$666.53+$1.50MMBXBF
3$17,016,490$15,394,610.53$14,405$814.59+$17.00MMBXBF
4$179,725,369$161,517,725.51$16,413$999.84+$179.71MMBXBF
5$1,786,627,353$1,594,321,207.48$18,795$1,232.92+$1786.61MMBXBF
6$16,723,791,389$14,812,100,121.30$21,639$1,527.95+$16723.77MMBXBF
7$147,473,158,468$129,578,701,682.00$25,057$1,903.80+$147473.13MMBXBF
8$1,225,690,132,710$1,067,893,853,149.49$29,197$2,385.87+$1225690.10MMBXBF
9$9,606,404,914,243$8,294,916,472,243.00$34,250$3,008.70+$9606404.88MMBXBF
10$71,037,548,348,739$60,758,695,090,499.19$40,467$3,819.61+$71037548.31MMBXBF

MBXBF vs EQR: Complete Analysis 2026

MBXBFStock

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

Full MBXBF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MBXBF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MBXBF vs SCHDMBXBF vs JEPIMBXBF vs OMBXBF vs KOMBXBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.